AstraZeneca在中国投资136亿元,扩建青岛设施,在改善监管和知识产权环境的情况下推出新药。 AstraZeneca invests $136M in China, expanding Qingdao facility and launching new drugs amid improved regulatory and IP environments.

AstraZeneca正在扩大其中国的业务,对其青岛设施投资1.36亿美元,以北京先前25亿美元的研发中心计划为基础。 AstraZeneca is expanding its China operations with a $136 million investment in its Qingdao facility, building on a prior $2.5 billion R&D center plan in Beijing. 在2025年中国国际进口博览会上重点介绍了这些举措,该公司在博览会上公布了两项新的乳腺癌药物和40多项创新疗法。 The moves were highlighted at the 2025 China International Import Expo, where the company unveiled two new breast cancer drugs and over 40 innovative treatments. 该公司指出,其四个全球生产枢纽向70多个国家供应药品。 该公司指出,中国提高监管效率、加强知识产权保护和支持性创新政策是其日益作出承诺的主要原因。 The company cited China’s improved regulatory efficiency, stronger intellectual property protections, and supportive innovation policies as key reasons for its growing commitment, noting its four global production hubs supply medicines to more than 70 countries.